The Manufacturers Life Insurance Company Grows Holdings in NantKwest, Inc. (NASDAQ:NK)


Share on StockTwits

The Manufacturers Life Insurance Company raised its position in NantKwest, Inc. (NASDAQ:NK) by 9.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 20,594 shares of the biotechnology company’s stock after buying an additional 1,783 shares during the period. The Manufacturers Life Insurance Company’s holdings in NantKwest were worth $275,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Panagora Asset Management Inc. lifted its holdings in NantKwest by 0.8% in the 4th quarter. Panagora Asset Management Inc. now owns 53,739 shares of the biotechnology company’s stock valued at $716,000 after purchasing an additional 408 shares in the last quarter. US Bancorp DE lifted its holdings in shares of NantKwest by 32.8% during the 4th quarter. US Bancorp DE now owns 3,984 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 984 shares during the period. Strs Ohio lifted its holdings in shares of NantKwest by 21.0% during the 3rd quarter. Strs Ohio now owns 7,500 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 1,300 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of NantKwest by 7.4% during the 4th quarter. Wells Fargo & Company MN now owns 44,564 shares of the biotechnology company’s stock worth $594,000 after acquiring an additional 3,085 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of NantKwest by 8.5% during the 4th quarter. Rhumbline Advisers now owns 40,328 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 3,170 shares during the period. Institutional investors own 9.38% of the company’s stock.

In related news, insider Barry J. Simon sold 22,100 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $23.09, for a total value of $510,289.00. Following the transaction, the insider now owns 3,192,640 shares in the company, valued at $73,718,057.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Barry J. Simon sold 11,304 shares of the firm’s stock in a transaction that occurred on Thursday, January 28th. The shares were sold at an average price of $20.53, for a total transaction of $232,071.12. Following the completion of the transaction, the insider now owns 3,207,166 shares in the company, valued at approximately $65,843,117.98. The disclosure for this sale can be found here. Insiders sold 115,474 shares of company stock worth $2,437,106 in the last 90 days. 71.73% of the stock is currently owned by insiders.

Shares of NK stock opened at $16.76 on Wednesday. The firm has a market cap of $1.83 billion, a P/E ratio of -23.61 and a beta of 2.61. NantKwest, Inc. has a 1-year low of $2.52 and a 1-year high of $45.42. The firm’s 50-day simple moving average is $29.13 and its 200-day simple moving average is $17.52.

Separately, Zacks Investment Research upgraded shares of NantKwest from a “sell” rating to a “hold” rating in a report on Tuesday, February 9th.

About NantKwest

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

See Also: What sectors are represented in the FTSE 100 index?

Want to see what other hedge funds are holding NK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NantKwest, Inc. (NASDAQ:NK).

Institutional Ownership by Quarter for NantKwest (NASDAQ:NK)

Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.